FDA updates safety rules for new medical and digital devices
美國食品藥物管理局更新新型醫療與數位裝置的安全規範
Food and Drug Administration (FDA) has announced a significant shift in its regulatory strategy for digital health.
為了促進創新，該機構正在簡化低風險數位健康工具的規範。
In a move to foster innovation, the agency is streamlining rules for low-risk digital health tools.
自 2026 年初起，提供臨床決策支援與一般健康穿戴式裝置的軟體，只要避免宣稱具有醫療級診斷功能，將面臨較少的障礙。
As of early 2026, software providing clinical decision support and general wellness wearables face fewer hurdles, provided they avoid medical-grade diagnostic claims.
這種「親創新（ㄑㄧㄣ ㄔㄨㄤˋ ㄒㄧㄣ）」的轉向，旨在減少消費者科技開發者的行政繁文縟節（ㄈㄢˊ ㄨㄣˊ ㄖㄨˋ ㄐㄧㄝˊ）。
This "pro-innovation" pivot aims to cut red tape for developers of consumer technology.
然而，FDA 同時對網路安全採取了更嚴格的「安全第一」方針。
However, the FDA is simultaneously taking a stricter "safety-first" approach regarding cybersecurity.
根據新規定，任何軟體驅動型醫療器材的製造商，現在必須提供詳細的軟體物料清單（SBOM），並在產品生命週期內證明其網路安全性。
Under new mandates, manufacturers of any software-enabled medical device must now provide a detailed Software Bill of Materials (SBOM) and prove cybersecurity throughout the product lifecycle.
這些規則將漏洞視為對病患安全的重大威脅。
These rules treat vulnerabilities as critical threats to patient safety.
透過區分簡單的健康應用程式與複雜的生命攸關（ㄧㄡ ㄍㄨㄢ）科技，FDA 正在重新定義其監管方式，以契合現代數位趨勢。
By distinguishing between simple wellness apps and complex life-critical technology, the FDA is redefining its oversight to match the modern digital landscape.
